Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease

NCT06548542 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06548542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06548542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Recruiting
Start date
September 4, 2024
Completion date
January 31, 2030
Enrollment
590 (estimated)
Sites
255

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease